India Plans New TB Strategy Amid Sharp Rise In Cases
Executive Summary
India is planning to mount a new, expanded strategy to combat the country’s worsening tuberculosis epidemic, amid rising concerns that the actual number of patients afflicted by the disease may be even higher than a new WHO estimate.
You may also be interested in...
Call For India Compulsory Licenses For Last Resort TB Drugs
Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses.
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.
FDA Approves First Generic Of Daraprim
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.